BioNTech SE22UA
▲ PositiveTechnologyrelevance
BNT113 from BioNTech is listed as a key therapy in development for head and neck squamous cell carcinoma, driving market growth.
Impact on assets 5
Biotech & Genomic Medicine
BioNTech SE
Johnson & JohnsonJNJ
▲ PositiveTechnologyrelevance
Amivantamab from Johnson & Johnson is listed as a key therapy in development for head and neck squamous cell carcinoma, driving market growth.
Health Care
Genmab ASGMAB
▲ PositiveTechnologyrelevance
Petosemtamab from Genmab is listed as a key therapy in development for head and neck squamous cell carcinoma, driving market growth.
Immutep Ltd ADRIMMP
Mentioned
Energy
ARKO Petroleum Corp.APC
Mentioned
Theme Impact 1
Off-coverage companies
Related news
Sweden▼
Alligator Bioscience Names CFO Johan Giléus as CEO, Søren Bregenholt to Step Down at Year-End
Alligator Bioscience has appointed Johan Giléus, currently CFO, as its new Chief Executive Officer effective 1 January 2027, with Søren Bregenholt remaining CEO until 31 December 2026 to ensure a seamless transition. Giléus will combine the CEO and CFO roles, reflecting the company's strategic refocusing towards its financial interest in the HER2-targeting antibody programme HLX22, as announced on 23 July 2026. Following the transition, Alligator will operate with a minimal organisation, supported by the Board of Directors and external consultants. Chairman Hans-Peter Ostler thanked Bregenholt for five years of leadership through a demanding period for the biotech sector, noting that the outcome with mitazalimab did not meet expectations, and said Giléus knows Alligator and its financial interest in HLX22 in depth. Giléus has more than 30 years of senior experience, including the last nine years in the Swedish biotech industry, and joined Alligator as CFO in August 2024 after leaving Deloitte Sweden's partnership in 2015. Alligator, listed on Nasdaq Stockholm under ATORX and headquartered in Lund, Sweden, has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset.
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics ▼Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Capital
Alligator Bioscience AB · Capital · Negative CEO transition to a minimal organisation after discontinuing mitazalimab development and refocusing on the HLX22 financial interest signals a strategic retreat
United States
Canada▲
Agenus Reports 48% Three-Year Survival for BOT+BAL in Recurrent Ovarian Cancer
Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial, showing an estimated 48% three-year overall survival for botensilimab plus balstilimab in recurrent ovarian cancer. The estimate was unchanged from two years, with median overall survival of 14.8 months, a 23% objective response rate among 35 evaluable patients, and a median duration of response of 9.7 months. At last follow-up, 25% of the 44 patients who received at least one dose, 11 in total, were alive and off all therapy. The heavily pretreated population had received a median of four prior lines of therapy, 77% had received bevacizumab and 57% a PARP inhibitor, and nearly three-quarters had platinum-resistant or refractory disease; estimated three-year survival was 47% in that subgroup and 61% in the 17 patients whose disease had progressed on a PARP inhibitor. The data were presented by Rebecca L. Porter of Dana-Farber Cancer Institute at the 2026 International Gynecologic Cancer Society Annual Global Meeting in Montréal, and Agenus said no new safety signals or treatment-related deaths were reported.
About megatrends
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
AGEN · Technology · Positive Agenus reported positive three-year follow-up data for botensilimab plus balstilimab in recurrent ovarian cancer, with 48% three-year overall survival and no new safety signals.
United States
United Kingdom
Japan▲9impact 4
AstraZeneca Invests $2 Billion in Summit Therapeutics for Ivonescimab Trials
AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced clinical collaboration agreements to test ivonescimab in combination with Datroway and sonesitatug vedotin across multiple tumour types, starting with a planned Phase III trial in first-line triple-negative breast cancer and gastrointestinal cancer. AstraZeneca's approximately US$2.00 billion equity investment via convertible preferred stock, alongside the co-funded oncology trials, prices the preferred stock at an implied US$18.36 per common share and targets roughly a 12% ownership stake in Summit. All parties retain full rights to their respective medicines. The investment strengthens Summit's funding and combination profile ahead of the HARMONi and HARMONi-3 readouts, though the U.S. FDA decision on the HARMONi BLA remains the key near-term catalyst and central source of risk. Summit's narrative projects $1.3 billion revenue and $223.0 million earnings by 2029, while some optimistic analysts model about US$2.7 billion of revenue and nearly US$289 million of earnings by 2029.
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
AZN.LSE · Capital · Positive AstraZeneca makes a ~$2.00 billion equity investment in Summit via convertible preferred stock and co-funds ivonescimab combination trials.
4568.JP · Technology · Neutral Daiichi Sankyo is a party to the clinical collaboration testing ivonescimab with its Datroway and sonesitatug vedotin, but no financial or efficacy outcome is disclosed.